lorazepam (Ativan)

How long the trials actually ran

We could not establish a longest trial length for lorazepam. That is a gap in what we can show you — not evidence that the trials ran long.

Approved before the Physician Labeling Rule, so no clinical studies section was ever required. The absence is the state of the public record, not a gap in our research.

The gap between how long the trials ran and how long people actually take these medications is the single most important thing on this page. It is not evidence that longer use is unsafe or ineffective. It is evidence that longer use was not what got tested.

How many Americans take lorazepam

Survey-based federal estimates, published with a lag of about two years. They count prescriptions filled, not outcomes.

9,095,808

prescriptions in the United States (2024)

2,178,409

people filling them (2024)

Prescriptions are down 43% since 2014. Whatever you decide about lorazepam, you are deciding alongside about 2,178,409 other people this year.

Source: ClinCalc DrugStats (Medical Expenditure Panel Survey (MEPS), Agency for Healthcare Research and Quality), CC BY-SA 4.0, release 2026.08.

What people report to the FDA about lorazepam

178,727

reports mentioning lorazepam, all time

137,468

filed as serious (a report-level flag covering every drug and outcome in the report)

Source: FDA Adverse Event Reporting System (FAERS), via openFDA, data through 2026-07-30.

Known interactions, from the label

The FDA label’s interactions section, verbatim. A pharmacist checking your actual medication list beats any published list — including this one.

FDA label for lorazepam, effective August 17, 2026 — DailyMed.

Who pays for lorazepam

Two claims datasets and one survey, covering different populations with different instruments — they cannot be reconciled by arithmetic, and where their sum crowds the all-payer estimate, that is a finding about the estimates rather than a percentage.

Medicare Part D

1,882,975 beneficiaries filled 8,137,337 claims in 2024 — 1,561,790 aged 65 and over, and 321,185 under 65. The under-65 group is not a picture of ordinary working-age adults: Medicare before 65 means the disabled and dual-eligible population — among the sickest, highest-need people in the program — and reading their utilization as typical adult use would be a category error.

Medicaid

At least 1,265,963 prescriptions in 2024 — a floor, because 156 of 669 national data rows are suppressed for privacy and contribute zero. Medicaid covers more children than any insurer in the country and publishes no age split — how much of this number is pediatric use is not knowable from public data.

All payers (survey estimate)

The MEPS-based estimate above puts the whole country at 9,095,808 prescriptions and 2,178,409 people in 2024. Subtracting the public programs from it would produce a number for everyone else — and we do not print that number, because subtracting a survey from claims counts manufactures precision that does not exist.

The population nobody counts

The commercially insured working-age adult — statistically, the likeliest person to be reading this page — is the one population with no public per-drug count anywhere. Private claims data exists and is sold, but nothing a patient can check is published. For children the record is thinner still: no public source counts pediatric use of lorazepam specifically; the closest the public record comes is condition-level treatment rates for children, which we have traced for one condition in how childhood ADHD got counted.

Sources: Medicare Part D Prescribers — by Geography and Drug, data.cms.gov, National rows, data year 2024 (published with ~17-month lag). Medicaid State Drug Utilization Data 2024, data.medicaid.gov, national aggregate rows. Retrieved 2026-09-01.

The approval, step by step

1. Step 1

   What the approval was actually based on

   Which studies did the FDA rely on, how long did they run, and who was in them?

   read the label on DailyMed

   Our reading

   Approved in 1977 under the old label format, and the current label still carries no clinical studies section — the trials the approval rested on are in FDA archives, not on the document your pharmacist can print. That absence is the state of the record, not a gap in our research. What the label does carry, prominently, is the benzodiazepine class boxed warning about dependence, withdrawal, and combination with opioids — added in 2020, forty-three years after approval. The label also states that the effectiveness of lorazepam in long-term use, beyond four months, has not been assessed by systematic clinical studies.

2. Step 2

   The approval

   When was it approved, under what application, and by whose review?

   Approved

   September 30, 1977

   Application

   NDA017794

   Review

   STANDARD

   Original sponsor

   Wyeth

   Holds it now

   Bausch Health

   Label submissions since

   29

   Source: openFDA Drugs@FDA, original application ORIG-1

3. Step 3

   What was added after it was on the market

   Which warnings arrived only after millions of people were already taking it?

   • The FDA strengthened the benzodiazepine warning in 2020

     43 years after approval

     In September 2020 the FDA required the boxed warning on every benzodiazepine to be rewritten. The wording matters: physical dependence can develop even when the medication is taken exactly as prescribed, and stopping abruptly or dropping the dose quickly can cause withdrawal reactions that include seizures and can be life-threatening.

     This is not a claim that the medication is bad or that you should stop taking it. It is the opposite. It is the reason not to stop on your own. The FDA's own instruction to prescribers is to taper gradually rather than stop, and to reassess dose and duration over time.

     Worth asking

     How long is the plan for me to be on this, what does my taper look like if we decide to come off, and how will we tell withdrawal apart from my original anxiety coming back.

     FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class — U.S. Food and Drug Administration (2020)

4. Step 4

   What independent research has found since

   What has been learned by people who were not selling it?

   • Withdrawal from these medications can take months, and NICE says so

     45 years after approval

     NICE guideline NG215 covers safe prescribing and managed withdrawal for five groups of medication: opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants. It is the closest thing there is to an official answer on how coming off actually goes.

     It states that withdrawal can be difficult and may take several months or more, that symptoms vary widely in type and severity, that they affect both physical and mental health, and that they can be delayed in onset and can persist. Two recommendations are worth quoting to a prescriber. Do not stop a medicine abruptly except in exceptional medical circumstances. And taper using a slow, stepwise reduction proportionate to the current dose, so the decrements get smaller as the dose gets lower — not a fixed cut each time.

     That last detail is the one most commonly missed. Gabapentinoids are the exception in the guideline and are reduced by a fixed amount at each step.

     Worth asking

     Can we write the taper down, what size are the steps near the end, and how long do I hold at each step before the next reduction.

     Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults (NG215) — National Institute for Health and Care Excellence (2022)

   • Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users

     41 years after approval

     Across 38 randomized trials (2,543 people trying to stop long-term benzodiazepines), no add-on medication reliably improved discontinuation success, leaving gradual dose tapering as the mainstay of coming off drugs like lorazepam.

     Worth asking

     If I want to come off lorazepam later, what taper schedule would you use, and over how many weeks or months?

     Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users — Baandrup L, et al. (2018)

   • Benzodiazepines for psychosis-induced aggression or agitation

     40 years after approval

     Across 20 small randomized trials (695 people), benzodiazepines - most often lorazepam - calmed acute psychotic agitation about as well as antipsychotics and caused fewer movement side effects, but the review rated the evidence quality poor.

     Worth asking

     If lorazepam is being used to settle acute agitation or crisis anxiety, what is the exit plan once the crisis has passed?

     Benzodiazepines for psychosis-induced aggression or agitation — Zaman H, et al. (2017)

   • A comparison of four treatments for generalized convulsive status epilepticus

     21 years after approval

     In a randomized double-blind trial of 518 patients with generalized convulsive status epilepticus, intravenous lorazepam stopped overt seizures in 64.9% of patients versus 43.6% with phenytoin, establishing it as a preferred first-line emergency treatment.

     Worth asking

     Lorazepam's strongest evidence is in emergency seizure care - for my anxiety, what evidence guides the dose and how long I should take it?

     A comparison of four treatments for generalized convulsive status epilepticus — Treiman DM, et al. (1998)

   • A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus

     24 years after approval

     In 205 people with out-of-hospital status epilepticus, paramedic-administered intravenous lorazepam terminated seizures in 59.1% of patients versus 21.1% with placebo (odds ratio 4.8), without increasing respiratory complications.

     Worth asking

     This trial shows lorazepam acts quickly and strongly - if I'm using it as-needed for anxiety, how do we keep as-needed from drifting into daily use?

     A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus — Alldredge BK, et al. (2001)

   • Cognitive effects of long-term benzodiazepine use: a meta-analysis

     27 years after approval

     Pooling 13 observational studies of people who had taken benzodiazepines for about 10 years on average, long-term users scored moderately worse than controls across every cognitive domain tested (mean effect size -0.74).

     Worth asking

     If I stay on lorazepam long term, how will we monitor for effects on memory and concentration?

     Cognitive effects of long-term benzodiazepine use: a meta-analysis — Barker MJ, et al. (2004)

5. Step 5

   What still is not known

   Which questions you might reasonably have has nobody answered yet?

   • The label itself says effectiveness beyond four months was never systematically assessed. How long has this prescription been running?
   • The dependence boxed warning arrived in 2020. What was the label telling prescribers for the forty-three years before that?
   • Twenty-nine submissions against the application, and the trials still are not on the label. What did they show?